Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat
about
CRF receptor antagonist astressin-B reverses and prevents alopecia in CRF over-expressing miceAstressin B, a nonselective corticotropin-releasing hormone receptor antagonist, prevents the inhibitory effect of ghrelin on luteinizing hormone pulse frequency in the ovariectomized rhesus monkeyCentral nesfatin-1 reduces dark-phase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor2 receptorCRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndromeThe Antidepressant-like Effects of Estrogen-mediated GhrelinNMR Structure of the First Extracellular Domain of Corticotropin-releasing Factor Receptor 1 (ECD1-CRF-R1) Complexed with a High Affinity AgonistLocal secretion of urocortin 1 promotes microvascular permeability during lipopolysaccharide-induced inflammationNeuroendocrine control of the gut during stress: corticotropin-releasing factor signaling pathways in the spotlight.Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.Corticotropin-releasing factor receptors and stress-related alterations of gut motor function.MALDI-MS analysis of peptides modified with photolabile arylazido groups.Facilitation of cardiac vagal activity by CRF-R1 antagonists during swim stress in ratsFrom Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases.Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF(2).Urocortin 1 inhibits rat leydig cell function.Cholinergic giant migrating contractions in conscious mouse colon assessed by using a novel noninvasive solid-state manometry method: modulation by stressors.Orexigenic response to tail pinch: role of brain NPY(1) and corticotropin releasing factor receptors.Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevanceStabilized helical peptides: overview of the technologies and therapeutic promises.Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins).Stressin1-A, a potent corticotropin releasing factor receptor 1 (CRF1)-selective peptide agonist.Central nesfatin-1 reduces the nocturnal food intake in mice by reducing meal size and increasing inter-meal intervals.The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.Corticotropin-releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long-Evans rats.Enhanced pelvic responses to stressors in female CRF-overexpressing mice.The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1-31)NH2 on bone formation and mechanical strength in ovariectomized rats.Peripheral urocortin inhibits gastric emptying and food intake in mice: differential role of CRF receptor 2.An optimized solid phase synthesis strategy--including on-resin lactamization--of astressin, its retro-, inverso-, and retro-inverso isomers as corticotropin releasing factor antagonists.Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys.Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats.Corticotropin-releasing factor receptor subtypes mediating nutritional suppression of estrous behavior in Syrian hamsters.Does IL-6 release ACTH by exerting a direct effect in the rat anterior pituitary.LPS inhibits fasted plasma ghrelin levels in rats: role of IL-1 and PGs and functional implications.
P2860
Q21091067-64139C1A-72BF-45EF-8823-CB53DA7482CBQ24649224-26849EEF-243B-4237-9BBE-6D4713501F78Q24657757-45C6F97D-1159-4553-BB4B-B429D7CC82F8Q24671910-17A01B7F-0CB4-425B-ADBD-FDBF02383BD8Q26786203-FE4922F9-EFEC-4116-B7F8-9E3FB4362081Q27664491-5F9F1502-9FBE-4704-989A-6C929CFF434FQ28564845-CEC175F4-F8A8-4933-B08C-419CC6B45A54Q30484216-67522DEE-4362-4A51-8E5F-C6823D6A3FACQ30502566-6D35E5C8-ED53-4D8F-8E94-4BBDC0830A15Q30542062-E9CD9EAA-8C3A-4E05-8114-AF6EC84A08EAQ31100269-011C14C1-3EF9-4642-BCA9-8007194E91A4Q33153854-929BB857-7DDC-4250-8FD6-38C8C618C853Q34357345-9044451E-B034-46E0-B906-F46FE06A9247Q35044361-840113F6-E1E4-43F4-BF53-562F43F775A7Q37034902-7543F1CD-2E80-4BE0-8739-C9C7FEC94359Q37227044-648BAFF5-50E5-413A-BC81-40D1362C0261Q37578127-56C83A9E-9068-4FB2-B7D0-9612F4CD0947Q37662647-087EB745-40CF-43F8-9EAA-C44E4C7B6D03Q38014489-BDCE1BA3-561D-49B5-8889-56C6DAFD5752Q40084135-F031D7A9-2744-46DD-AEE4-B9D3DCF18211Q41370719-9A01DEB2-FDDD-4BC2-8EED-4CCB30F36892Q41483576-0AFA1B80-7F67-4A75-B4C5-051BBE1B9C78Q42701005-AAE76D2E-1600-44DD-9C84-BB0608B47916Q43323885-35932C3F-DCB6-400F-B6CC-E1C787898F22Q43342584-9E2F3504-DBA7-4A36-8663-DC1DA499DED4Q43580099-DC097969-9D1F-40A4-BCA3-600BCA7EBF5FQ43771149-267C8E7D-7E03-4F7B-963B-F8142DF5EC9EQ43851708-61EB63F5-2E86-4587-A1DE-8C82CBFC0822Q44784145-EFDC8C18-F63A-42BC-A9FC-A4ECB17F112CQ46325802-A7A8F5E8-2648-4289-9D66-54928E9DB5EEQ46438849-FB2DB34A-6C9D-406F-92C7-7E3C14CB9355Q47743864-5215EBBA-8247-4D62-BF45-C76F228A00D3Q51490296-D868FDA0-59E9-4F98-8DB0-BD127BA10822
P2860
Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Constrained corticotropin rele ...... duration of action in the rat
@ast
Constrained corticotropin rele ...... duration of action in the rat
@en
Constrained corticotropin rele ...... duration of action in the rat
@nl
type
label
Constrained corticotropin rele ...... duration of action in the rat
@ast
Constrained corticotropin rele ...... duration of action in the rat
@en
Constrained corticotropin rele ...... duration of action in the rat
@nl
prefLabel
Constrained corticotropin rele ...... duration of action in the rat
@ast
Constrained corticotropin rele ...... duration of action in the rat
@en
Constrained corticotropin rele ...... duration of action in the rat
@nl
P2093
P356
P1476
Constrained corticotropin rele ...... duration of action in the rat
@en
P2093
A Corrigan
C L Rivier
J E Rivier
S L Lahrichi
P304
P356
10.1021/JM9902133
P407
P577
1999-08-12T00:00:00Z